TEL/AML1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL

被引：0
|
作者：
E Fronkova
J Madzo
J Zuna
L Reznickova
K Muzikova
O Hrusak
J Stary
J Trka
机构：
[1] 2nd Medical School,CLIP – Childhood Leukaemia Investigation Prague
[2] Charles University,Department of Paediatric Haematology/Oncology
[3] 2nd Medical School,Department of Immunology
[4] Charles University,undefined
[5] 2nd Medical School,undefined
[6] Charles University,undefined
来源：
Leukemia | 2005年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1296 / 1297
页数：1
相关论文
共 50 条
  • [41] Novel 5′ exonuclease-based real-time PCR assay for the detection of TEL-AML1 fusion in childhood acute lymphoblastic leukemia (ALL).
    Seeger, K
    Kreuzer, KA
    Schmidt, CA
    Buchwald, D
    Lass, U
    Schmitt, G
    Taube, T
    Köchling, J
    Beyermann, B
    Huhn, D
    Henze, G
    BLOOD, 1998, 92 (10) : 392A - 393A
  • [42] TEL/AML1 transcript in Childhood. Acute lymphoblastic leukemia: A new candidate for minimal residual disease study rather than a new prognosis factor?
    Chambost, H
    Michel, G
    Thuret, I
    Toiron, Y
    Brunet, C
    Capodano, AM
    Sainty, D
    Maraninchi, D
    Gabert, J
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 216 - 216
  • [43] Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma
    Puig, Noemi
    Sarasquete, Maria E.
    Alcoceba, Miguel
    Balanzategui, Ana
    Chillon, Maria C.
    Sebastian, Elena
    Diaz, Marcos G.
    San Miguel, Jesus F.
    Garcia-Sanz, Ramon
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 89 (04) : 328 - 335
  • [44] CLONE-SPECIFIC IGH PLASMIDS AS AN ALTERNATIVE STANDARD FOR ASSESSMENT OF MINIMAL RESIDUAL DISEASE BY REAL-TIME QUANTITATIVE PCR IN FOLLICULAR LYMPHOMA
    Laubenstein, T.
    Kneba, M.
    Pott, C.
    HAEMATOLOGICA, 2016, 101 : 480 - 481
  • [45] Quantification of chemokines by real-time reverse transcriptase PCR: applications in type 1 diabetes
    Overbergh, L
    Gysemans, C
    Mathieu, C
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2006, 6 (01) : 51 - 64
  • [46] Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (vol 32, pg 345, 2019)
    Pfeifer, H.
    Cazzaniga, G.
    van der Velden, V. H. J.
    Cayuela, J. M.
    Schafer, B.
    Spinelli, O.
    Akiki, S.
    Avigad, S.
    Bendit, I.
    Borg, K.
    Cave, H.
    Elia, L.
    Reshmi, S. C.
    Gerrard, G.
    Hayette, S.
    Hermanson, M.
    Juh, A.
    Jurcek, T.
    Chillon, M. C.
    Homburg, C.
    Martinelli, G.
    Kairisto, V.
    Lange, T.
    Lion, T.
    Mueller, M. C.
    Pane, F.
    Rai, L.
    Damm-Welk, C.
    Sacha, T.
    Schnittger, S.
    Touloumenidou, T.
    Valerhaugen, H.
    Vandenberghe, P.
    Zuna, J.
    Serve, H.
    Herrmann, E.
    Markovic, S.
    van Dongen, J. J. M.
    Ottmann, O. G.
    LEUKEMIA, 2020, 34 (07) : 1970 - 1970
  • [47] Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects
    V H J van der Velden
    A Hochhaus
    G Cazzaniga
    T Szczepanski
    J Gabert
    J J M van Dongen
    Leukemia, 2003, 17 : 1013 - 1034
  • [48] Quantitative nested real-time RT-PCR specific for tyrosinase transcripts to quantitate minimal residual disease
    Max, N
    Wolf, K
    Thiel, E
    Keilholz, U
    CLINICA CHIMICA ACTA, 2002, 317 (1-2) : 39 - 46
  • [49] Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects
    van der Velden, VHJ
    Hochhaus, A
    Cazzaniga, G
    Szczepanski, T
    Gabert, J
    van Dongen, JJM
    LEUKEMIA, 2003, 17 (06) : 1013 - 1034
  • [50] TEL-AML1 alternative transcripts in pediatric ALL: Significance for minimal residual disease testing.
    Bartolo, C
    Morales, T
    Beaubier, NT
    Willman, CL
    Viswanatha, DS
    BLOOD, 1999, 94 (10) : 287A - 287A
12345